73 results
Page 2 of 4
6-K
EX-99.2
v8ff ggsogp
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
F-3
4jo7sqc95zw 8z1t7uns
10 Nov 21
Shelf registration (foreign)
5:23pm
6-K
EX-99.2
sm7yo8tm9xf
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K/A
EX-99.2
0fcxylizzlh92v
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K/A
EX-99.5
htns9cjg69r8p gau
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.2
thtpbxc
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.5
ndbil9 auv5
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.2
4tp 3js2acno
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.1
fbe3gn
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am
6-K
EX-99.2
nzg 7fils03su9gqm
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
EX-99.1
146sl791pccw3 t2
22 Apr 21
ObsEva Annual General Meeting 2021
6:31am
6-K
EX-1.1
97i07
5 Mar 21
Current report (foreign)
8:15am
424B5
czq0oo
5 Mar 21
Prospectus supplement for primary offering
7:55am
6-K
EX-99.1
4w1h 91cez
5 Mar 21
ObsEva Announces Year End 2020 Financial Results
7:21am
6-K
EX-1.1
5e6aexmy
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
EX-10.1
ved5j vs7
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
z1cb5rwyg7 82
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
cf3qs7
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.2
nbx6yv 649vgr98oxt
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am